Roubaix Capital LLC Has $3.01 Million Holdings in STAAR Surgical (NASDAQ:STAA)

Roubaix Capital LLC cut its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 10.0% in the third quarter, HoldingsChannel reports. The fund owned 81,114 shares of the medical instruments supplier’s stock after selling 9,058 shares during the quarter. Roubaix Capital LLC’s holdings in STAAR Surgical were worth $3,013,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Sei Investments Co. boosted its position in STAAR Surgical by 2.7% during the 2nd quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock worth $718,000 after acquiring an additional 394 shares during the period. Texas Permanent School Fund Corp lifted its holdings in shares of STAAR Surgical by 1.0% during the 1st quarter. Texas Permanent School Fund Corp now owns 42,577 shares of the medical instruments supplier’s stock valued at $1,630,000 after buying an additional 407 shares during the last quarter. Creative Planning lifted its holdings in shares of STAAR Surgical by 8.0% during the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 408 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of STAAR Surgical by 3.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after buying an additional 418 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC lifted its holdings in shares of STAAR Surgical by 2.3% during the 2nd quarter. Linden Thomas Advisory Services LLC now owns 20,721 shares of the medical instruments supplier’s stock valued at $987,000 after buying an additional 469 shares during the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.

STAAR Surgical Price Performance

Shares of NASDAQ:STAA opened at $29.49 on Thursday. The business’s fifty day moving average price is $32.06 and its two-hundred day moving average price is $38.76. STAAR Surgical has a fifty-two week low of $26.66 and a fifty-two week high of $52.68. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 86.74 and a beta of 0.59.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). The business had revenue of $99.01 million during the quarter, compared to analyst estimates of $95.22 million. STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. STAAR Surgical’s revenue for the quarter was up 7.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 EPS. Research analysts expect that STAAR Surgical will post 0.16 EPS for the current fiscal year.

Insiders Place Their Bets

In other STAAR Surgical news, Director Arthur C. Butcher acquired 1,315 shares of STAAR Surgical stock in a transaction on Monday, August 12th. The shares were bought at an average price of $37.99 per share, with a total value of $49,956.85. Following the completion of the purchase, the director now owns 4,208 shares in the company, valued at $159,861.92. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 1.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on STAA shares. Canaccord Genuity Group reduced their price target on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating for the company in a report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, September 19th. Stifel Nicolaus reduced their price target on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a report on Monday, August 26th. BTIG Research boosted their target price on STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Morgan Stanley lowered STAAR Surgical from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $50.00 to $37.00 in a report on Monday, July 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $45.57.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.